Bisphophonates in CKD patients with low bone mineral density

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Liu, Wen Chih ^a   Yen, Jen Fen ^a   Lang, Cheng Lin ^b   Yan, Ming Tso ^c   Lu, Kuo Cheng ^d  

^a Department of Nursing Tsao Tun Psychiatric Center Ministry of Health and Welfare   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT;

BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CHRONIC KIDNEY DISEASE; DRUG ABSORPTION; DRUG MECHANISM; FRAGILITY FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; LOW BONE MINERAL DENSITY; META ANALYSIS; METABOLIC BONE DISEASE; MINERAL METABOLISM; OSTEOMALACIA; OSTEOPOROSIS; RENAL OSTEODYSTROPHY; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION; AGED; ATHEROSCLEROSIS; BIOPSY; BONE; CALCINOSIS; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; FEMALE; KIDNEY TUBULE NECROSIS; MALE; MIDDLE AGED; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATHOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CALCINOSIS; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OSTEOCLASTS; OSTEOMALACIA; OSTEOPOROSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 84896323285     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/837573     Document Type: Review

References (100)

1. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G., Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney International 2006 69 11 1945 1953 2-s2.0-33645757920 10.1038/sj.ki.5000414 (Pubitemid 43924257)
2. Melton L. J. III, Epidemiology worldwide. Endocrinology and Metabolism Clinics of North America 2003 32 1 1 13 2-s2.0-0037301067 10.1016/S0889-8529(02) 00061-0 (Pubitemid 36378631)
3. Burge R., Dawson-Hughes B., Solomon D. H., Wong J. B., King A., Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. Journal of Bone and Mineral Research 2007 22 3 465 475 2-s2.0-34247194211 10.1359/jbmr.061113 (Pubitemid 46797130)
4. Klawansky S., Komaroff E., Cavanaugh P. F. Jr., Mitchell D. Y., Gordon M. J., Connelly J. E., Ross S. D., Relationship between age, renal function and bone mineral density in the US population. Osteoporosis International 2003 14 7 570 576 2-s2.0-0042026882 10.1007/s00198-003-1435-y (Pubitemid 36975556)
5. Hsu C.-Y., Cummings S. R., McCulloch C. E., Chertow G. M., Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney International 2002 61 5 1814 1820 2-s2.0-0036236195 10.1046/j.1523-1755. 2002.00306.x (Pubitemid 34437936)
6. Riggs B. L., Melton L. J. III, The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995 17 5, supplement 505S 511S 2-s2.0-0028799124
7. Gal-Moscovici A., Sprague S. M., Osteoporosis and chronic kidney disease. Seminars in Dialysis 2007 20 5 423 430 2-s2.0-34748859259 10.1111/j.1525-139X. 2007.00319.x
8. Eisman J. A., Civitelli R., Adami S., Czerwinski E., Recknor C., Prince R., Reginster J.-Y., Zaidi M., Felsenberg D., Hughes C., Mairon N., Masanauskaite D., Reid D. M., Delmas P. D., Recker R. R., Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 2008 35 3 488 497 2-s2.0-40649109120 (Pubitemid 351374427)
9. Black D. M., Delmas P. D., Eastell R., Reid I. R., Boonen S., Cauley J. A., Cosman F., Lakatos P., Ping C. L., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T. F., Sellmeyer D., Eriksen E. F., Cummings S. R., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine 2007 356 18 1809 1822 2-s2.0-34247866550 10.1056/NEJMoa067312 (Pubitemid 46698462)
10. Wilkins C. H., Birge S. J., Prevention of osteoporotic fractures in the elderly. American Journal of Medicine 2005 118 11 1190 1195 2-s2.0-27644470998 10.1016/j.amjmed.2005.06.046 (Pubitemid 41566517)
11. Benhamou C.-L., Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007 74 1 39 47 2-s2.0-33846951516 10.1016/j.jbspin.2006.06.004 (Pubitemid 46242204)
12. Miller P. D., Diagnosis and treatment of osteoporosis in chronic renal disease. Seminars in Nephrology 2009 29 2 144 155 2-s2.0-64049106584 10.1016/j.semnephrol.2009.01.007
13. Baim S., Binkley N., Bilezikian J. P., Kendler D. L., Hans D. B., Lewiecki E. M., Silverman S., Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. Journal of Clinical Densitometry 2008 11 1 75 91 2-s2.0-42649112056 10.1016/j.jocd.2007.12.007 (Pubitemid 351602189)
14. Assessment of Fracture Risk its Application to Screening for Postmenopausal Osteoporosis, Report of a WHO Study Group 1994 843 World Health Organization Technical Report Series
15. Bouxsein M. L., Non-invasive measurements of bone strength: promise and peril. Journal of Musculoskeletal Neuronal Interactions 2004 4 4 404 405 2-s2.0-12344286081 (Pubitemid 40124881)
16. Seeman E., Bone quality: the material and structural basis of bone strength. Journal of Bone and Mineral Metabolism 2008 26 1 1 8 2-s2.0-37349017937 10.1007/s00774-007-0793-5 (Pubitemid 350308006)
17. Nih Consensus Development Panel on Osteoporosis Prevention, D., and Therapy, Osteoporosis prevention, diagnosis, and therapy. The Journal of the American Medical Association 2001 285 785 795
18. Miller P. D., Fragility fractures in chronic kidney disease: an opinion-based approach. Cleveland Clinic Journal of Medicine 2009 76 12 715 723 2-s2.0-74049101459 10.3949/ccjm.76a.08108
19. Martin K. J., González E. A., Metabolic bone disease in chronic kidney disease. Journal of the American Society of Nephrology 2007 18 3 875 885 2-s2.0-33947264651 10.1681/ASN.2006070771 (Pubitemid 46434504)
20. Wehrli F. W., Leonard M. B., Saha P. K., Gomberg B. R., Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. Journal of Magnetic Resonance Imaging 2004 20 1 83 89 2-s2.0-3042796042 10.1002/jmri.20085 (Pubitemid 38857520)
21. Baim S., Miller P. D., Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. Journal of Bone and Mineral Research 2009 24 4 561 574 2-s2.0-65549102548 10.1359/jbmr.090203
22. Calvo M. S., Eyre D. R., Gundberg C. M., Molecular basis and clinical application of biological markers of bone turnover. Endocrine Reviews 1996 17 4 333 368 2-s2.0-0029799613 10.1210/er.17.4.333 (Pubitemid 26277979)
23. Clarke B., Normal bone anatomy and physiology. Clinical Journal of the American Society of Nephrology 2008 3 supplement 3 S131 S139 2-s2.0-58149387662 10.2215/CJN.04151206
24. Seeman E., The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinology and Metabolism Clinics of North America 2003 32 1 25 38 2-s2.0-0037300524 10.1016/S0889-8529(02)00078-6 (Pubitemid 36378633)
25. Taylor A. K., Lueken S. A., Libanati C., Baylink D. J., Biochemical markers of bone, turnover for the clinical assessment of bone metabolism. Rheumatic Disease Clinics of North America 1994 20 3 589 607 2-s2.0-0028100335 (Pubitemid 24271579)
26. Hanson D. A., Weis M. A. E., Bollen A.-M., Maslan S. L., Singer F. R., Eyre D. R., A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. Journal of Bone and Mineral Research 1992 7 11 1251 1258 2-s2.0-0026676875 (Pubitemid 23000964)
27. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P. D., Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Journal of Bone and Mineral Research 1995 10 4 641 649 2-s2.0-0028960818
28. Ritz E., Stefanski A., Rambausek M., The role of the parathyroid glands in the uremic syndrome. American Journal of Kidney Diseases 1995 26 5 808 813 2-s2.0-0028864696
29. Avbersek-Luznik I., Balon B. P., Rus I., Marc J., Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrology Dialysis Transplantation 2005 20 3 566 570 2-s2.0-15044348241 10.1093/ndt/gfh672 (Pubitemid 40378426)
30. Aoki S., Honma M., Kariya Y., Nakamichi Y., Ninomiya T., Takahashi N., Udagawa N., Suzuki H., Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. Journal of Bone and Mineral Research 2010 25 9 1907 1921 2-s2.0-77956839811 10.1002/jbmr.89
31. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., Smith E., Bonadio J., Goldstein S., Gundberg C., Bradley A., Karsenty G., Increased bone formation in osteocalcin-deficient mice. Nature 1996 382 6590 448 452 2-s2.0-15844412402 10.1038/382448a0 (Pubitemid 26264860)
32. Spaulding C. M., Young G., Osteitis fibrosa cystica and chronic renal failure. Journal of the American Podiatric Medical Association 1997 87 5 238 240 2-s2.0-0031132586 (Pubitemid 127686938)
33. Gonzalez E. A., Martin K. J., Aluminum and renal osteodystrophy: a diminishing clinical problem. Trends in Endocrinology and Metabolism 1992 3 10 371 375 2-s2.0-0027050642 10.1016/1043-2760(92)90004-K (Pubitemid 23014555)
34. Coen G., Manni M., Addari O., Ballanti P., Pasquali M., Chicca S., Mazzaferro S., Napoletano I., Napoletano I., Sardella D., Bonucci E., Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment. Mineral and Electrolyte Metabolism 1995 21 6 375 382 2-s2.0-0028886033
35. Cannata-Andia J. B., Harrington J. T., Martinez-Maldonado M., Massari P., Schor N., Carlos Ayus J., Valderrabano F., Frazao J., Coburn J. W., Weisinger J. R., Heilberg I. P., Ferreira A., Hypokinetic azotemic osteodystrophy. Kidney International 1998 54 3 1000 1016 2-s2.0-0031714473 10.1046/j.1523-1755.1998. 00080.x (Pubitemid 28397425)
36. Moe S. M., Drüeke T., Improving global outcomes in mineral and bone disorders. Clinical Journal of the American Society of Nephrology 2008 3 supplement S127 S130 2-s2.0-58149374010 10.2215/CJN.04331206
37. Gordon P. L., Frassetto L. A., Management of osteoporosis in CKD Stages 3 to 5. American Journal of Kidney Diseases 2010 55 5 941 956 2-s2.0-77951577555 10.1053/j.ajkd.2010.02.338
38. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements 2009 113 S1 S130 10.1038/ki.2009.188
39. Nickolas T. L., Leonard M. B., Shane E., Chronic kidney disease and bone fracture: a growing concern. Kidney International 2008 74 6 721 731 2-s2.0-50849132537 10.1038/ki.2008.264
40. Genant H. K., Lang T. F., Engelke K., Fuerst T., Glüer C.-C., Majumdar S., Jergas M., Advances in the noninvasive assessment of bone density, quality, and structure. Calcified Tissue International 1996 59 1, supplement S10 S15 2-s2.0-0029801951 10.1007/s002239900169 (Pubitemid 26371196)
41. Roschger P., Paschalis E. P., Fratzl P., Klaushofer K., Bone mineralization density distribution in health and disease. Bone 2008 42 3 456 466 2-s2.0-39149107458 10.1016/j.bone.2007.10.021
42. Hung K. C., Huang C. Y., Liu C. C., Serum bone resorption markers after parathyroidectomy for renal hyperparathyroidism: correlation analyses for the cross-linked N-telopeptide of collagen I and tartrate-resistant acid phosphatase. The Scientific World Journal 2012 2012 503945 10.1100/2012/503945
43. Whyte M. P., Greenberg C. R., Salman N. J., Bober M. B., McAlister W. H., Wenkert D., Van Sickle B. J., Simmons J. H., Edgar T. S., Bauer M. L., Hamdan M. A., Bishop N., Lutz R. E., McGinn M., Craig S., Moore J. N., Taylor J. W., Cleveland R. H., Cranley W. R., Lim R., Thacher T. D., Mayhew J. E., Downs M., Millán J. L., Skrinar A. M., Crine P., Landy H., Enzyme-replacement therapy in life-threatening hypophosphatasia. The New England Journal of Medicine 2012 366 10 904 913 2-s2.0-84857878810 10.1056/NEJMoa1106173
44. Russell R. G. G., Watts N. B., Ebetino F. H., Rogers M. J., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 2008 19 6 733 759 2-s2.0-43049109229 10.1007/s00198-007-0540-8
45. Razzaque M. S., Lanske B., The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. Journal of Endocrinology 2007 194 1 1 10 2-s2.0-34250649644 10.1677/JOE-07-0095 (Pubitemid 47162881)
46. Troehler U., Bonjour J. P., Fleisch H., Renal secretion of diphosphonates in rats. Kidney International 1975 8 1 6 13 2-s2.0-0016740688
47. Lin J. H., Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996 18 2 75 85 2-s2.0-0029886359 10.1016/8756-3282(95)00445-9 (Pubitemid 26092586)
48. Russell R. G. G., Rogers M. J., Frith J. C., Luckman S. P., Coxon F. P., Benford H. L., Croucher P. I., Shipman C., Fleisch H. A., The pharmacology of bisphosphonates and new insights into their mechanisms of action. Journal of Bone and Mineral Research 1999 14 supplement 2 53 65 2-s2.0-0032859149 (Pubitemid 29455800)
49. Negri A. L., Vascular calcifications in chronic kidney disease: are there new treatments? Current Vascular Pharmacology 2005 3 2 181 184 2-s2.0-18044399154 10.2174/1570161053586877 (Pubitemid 40601586)
50. Toussaint N. D., Kerr P. G., Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology 2007 12 5 500 509 2-s2.0-34548441581 10.1111/j.1440-1797.2007.00823.x (Pubitemid 47366641)
51. Tamura K., Suzuki Y., Matsushita M., Fujii H., Miyaura C., Aizawa S., Kogo H., Prevention of aortic calcification by etidronate in the renal failure rat model. European Journal of Pharmacology 2007 558 1-3 159 166 2-s2.0-33847275569 10.1016/j.ejphar.2006.12.006 (Pubitemid 46328889)
52. Frith J. C., Mönkkönen J., Blackburn G. M., Russell R. G. G., Rogers M. J., Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β γ -dichloromethylene) triphosphate, by mammalian cells in vitro. Journal of Bone and Mineral Research 1997 12 9 1358 1367 2-s2.0-1842405434 10.1359/jbmr.1997.12.9.1358 (Pubitemid 27375378)
53. Coxon F. P., Rogers M. J., The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcified Tissue International 2003 72 1 80 84 2-s2.0-0041709185 10.1007/s00223-002-2017-2 (Pubitemid 36918941)
54. Masarachia P. J., Weinreb M., Balena R., Rodan G. A., Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996 19 3 281 290 2-s2.0-0030227986 10.1016/8756-3282(96)00182-2 (Pubitemid 26305769)
55. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., Kiyoki M., Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995 16 2 235 245 2-s2.0-0029164610 10.1016/8756-3282(94)00035-X
56. Bukowski J. F., Dascher C. C., Das H., Alternative bisphosphonate targets and mechanisms of action. Biochemical and Biophysical Research Communications 2005 328 3 746 750 2-s2.0-13444271786 10.1016/j.bbrc.2004.11.075 (Pubitemid 40208312)
57. Cunningham J., Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. Journal of the American Society of Nephrology 2007 18 1 223 234 2-s2.0-33846021310 10.1681/ASN.2006050427 (Pubitemid 46053435)
58. Miller P. D., Roux C., Boonen S., Barton I. P., Dunlap L. E., Burgio D. E., Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Journal of Bone and Mineral Research 2005 20 12 2105 2115 2-s2.0-28144453342 10.1359/JBMR.050817 (Pubitemid 41698774)
59. Miller P. D., Anti-resorptives in the management of osteoporosis. Best Practice and Research 2008 22 5 849 868 2-s2.0-56349160610 10.1016/j.beem.2008. 07.004
60. Perazella M. A., Markowitz G. S., Bisphosphonate nephrotoxicity. Kidney International 2008 74 11 1385 1393 2-s2.0-56549084704 10.1038/ki.2008.356
61. Boonen S., Sellmeyer D. E., Lippuner K., Orlov-Morozov A., Abrams K., Mesenbrink P., Eriksen E. F., Miller P. D., Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International 2008 74 5 641 648 2-s2.0-49749093393 10.1038/ki.2008.193
62. Toussaint N. D., Elder G. J., Kerr P. G., Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clinical Journal of the American Society of Nephrology 2009 4 1 221 233 2-s2.0-64049097169 10.2215/CJN.02550508
63. Miller P. D., Is there a role for bisphosphonates in chronic kidney disease? Seminars in Dialysis 2007 20 3 186 190 2-s2.0-34249990893 10.1111/j.1525-139X.2007.00271.x
64. Wetmore J. B., Benet L. Z., Kleinstuck D., Frassetto L., Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology 2005 10 4 393 399 2-s2.0-28444440170 10.1111/j.1440-1797.2005.00436.x (Pubitemid 41725517)
65. Miller P. D., The role of bone biopsy in patients with chronic renal failure. Clinical Journal of the American Society of Nephrology 2008 3 supplement 3 S140 S150 2-s2.0-58149400642 10.2215/CJN.02430508
66. Ferreira M. A., Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrology Dialysis Transplantation 2000 15 supplement 5 8 14 2-s2.0-0033789919
67. Ureña P., Hruby M., Ferreira A., Ang K. S., de Vernejoul M.-C., Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. Journal of the American Society of Nephrology 1996 7 3 506 512 2-s2.0-0029921693 (Pubitemid 26128321)
68. Bergner R., Bisphosphonate therapy in renal osteodystrophy-a review. Journal of Nephrology 2013 26 450 455
69. Buttazzoni M., Rosa Diez G. J., Jager V., Crucelegui M. S., Algranati S. L., Plantalech L., Elimination and clearance of pamidronate by haemodialysis. Nephrology 2006 11 3 197 200 2-s2.0-33744832003 10.1111/j.1440-1797.2006.00569.x (Pubitemid 43829437)
70. Lu K.-C., Yeung L.-K., Lin S.-H., Lin Y.-F., Chu P., Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. American Journal of Kidney Diseases 2003 42 6 1221 1227 2-s2.0-0344826837 10.1053/j.ajkd.2003.08.023 (Pubitemid 37486766)
71. Huang C. Y., Zheng C. M., Wu C. C., Lo L., Lu K. C., Chu P., Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Nephron Clinical Practice 2012 122 93 101
72. Rogers M. J., Xiong X., Ji X., Mönkkönen J., Russell R. G. G., Williamson M. P., Ebetino F. H., Watts D. J., Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharmaceutical Research 1997 14 5 625 630 2-s2.0-0030947272 10.1023/A:1012157212793 (Pubitemid 27220281)
73. Ylitalo R., Monkkonen J., Ylä-Herttuala S., Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life Sciences 1997 62 5 413 422 2-s2.0-0031587593 10.1016/S0024-3205(97)01134-X (Pubitemid 28018194)
74. Ylitalo R., Bisphosphonates and atherosclerosis. General Pharmacology 2000 35 6 287 296 2-s2.0-1842853752 10.1016/S0306-3623(01)00121-5 (Pubitemid 34258510)
75. Kramsch D. M., Aspen A. J., Rozler L. J., Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 1981 213 4515 1511 1512 2-s2.0-0019465841 (Pubitemid 11031236)
76. Zhu B.-Q., Sun Y.-P., Sievers R. E., Isenberg W. M., Moorehead T. J., Parmley W. W., Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology 1994 85 6 370 377 2-s2.0-0028605934
77. Ylitalo R., Oksala O., Ylä-Herttuala S., Ylitalo P., Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. Journal of Laboratory and Clinical Medicine 1994 123 5 769 776 2-s2.0-0028431884
78. Koshiyama H., Nakamura Y., Tanaka S., Minamikawa J., Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2000 85 8 2793 2796 2-s2.0-0034456560 10.1210/jc.85.8.2793 (Pubitemid 32269153)
79. Chen N. X., O'Neill K. D., Duan D., Moe S. M., Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney International 2002 62 5 1724 1731 2-s2.0-0036406957 10.1046/j.1523-1755.2002. 00625.x (Pubitemid 35286280)
80. Giachelli C. M., Vascular calcification: in vitro evidence for the role of inorganic phosphate. Journal of the American Society of Nephrology 2003 14 4 S300 S304 2-s2.0-0043037220 (Pubitemid 37052394)
81. Fleisch H. A., Russell R. G., Bisaz S., Mühlbauer R. C., Williams D. A., The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. European Journal of Clinical Investigation 1970 1 1 12 18 2-s2.0-0014759515
82. Russell R. G., Smith R., Bishop M. C., Price D. A., Treatment of myositis ossificans progressiva with a diphosphonate. The Lancet 1972 1 7740 10 11 2-s2.0-0015258760
83. London G. M., Marty C., Marchais S. J., Guerin A. P., Metivier F., De Vernejoul M.-C., Arterial calcifications and bone histomorphometry in end-stage renal disease. Journal of the American Society of Nephrology 2004 15 7 1943 1951 2-s2.0-3042528668 10.1097/01.ASN.0000129337.50739.48 (Pubitemid 38822076)
84. Tomiyama C., Carvalho A. B., Higa A., Jorgetti V., Draibe S. A., Canziani M. E. F., Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. Journal of Bone and Mineral Research 2010 25 3 499 504 2-s2.0-77953448102 10.1359/jbmr.090735
85. Barreto D. V., Barreto F. D. C., de Carvalho A. B., Cuppari L., Draibe S. A., Dalboni M. A., Moyses R. M. A., Neves K. R., Jorgetti V., Miname M., Santos R. D., Canziani M. E. F., Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. American Journal of Kidney Diseases 2008 52 6 1139 1150 2-s2.0-56049127121 10.1053/j.ajkd.2008.06.024
86. Toussaint N. D., Lau K. K., Strauss B. J., Polkinghorne K. R., Kerr P. G., Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. American Journal of Kidney Diseases 2010 56 1 57 68 2-s2.0-77953687445 10.1053/j.ajkd.2009.12.039
87. Cannata-Andia J. B., Roman-Garcia P., Hruska K., The connections between vascular calcification and bone health. Nephrology Dialysis Transplantation 2011 26 11 3429 3436 2-s2.0-80155171819 10.1093/ndt/gfr591
88. Viaene L., Behets G. J., Claes K., Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrology, Dialysis, Transplantation 2013 28 12 3024 3030 10.1093/ndt/gft039
89. Ott S. M., Bisphosphonate safety and efficacy in chronic kidney disease. Kidney International 2012 82 833 835
90. Persy V., De Broe M., Ketteler M., Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney International 2006 70 9 1537 1538 2-s2.0-33750219692 10.1038/sj.ki.5001899 (Pubitemid 44606986)
91. Shiraishi N., Kitamura K., Miyoshi T., Adachi M., Kohda Y., Nonoguchi H., Misumi S., Maekawa Y., Murayama T., Tomita M., Tomita K., Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. American Journal of Kidney Diseases 2006 48 1 151 154 2-s2.0-33745219882 10.1053/j.ajkd.2006.04.062
92. Monney P., Nguyen Q.-V., Perroud H., Descombes E., Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrology Dialysis Transplantation 2004 19 8 2130 2132 2-s2.0-4344618247 10.1093/ndt/gfh305 (Pubitemid 39139649)
93. Markowitz G. S., Appel G. B., Fine P. L., Fenves A. Z., Loon N. R., Jagannath S., Kuhn J. A., Dratch A. D., D'Agati V. D., Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. Journal of the American Society of Nephrology 2001 12 6 1164 1172 2-s2.0-0035007762 (Pubitemid 32472629)
94. Sauter M., Jülg B., Porubsky S., Cohen C., Fischereder M., Sitter T., Schlondorff D., Gröne H.-J., Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? American Journal of Kidney Diseases 2006 47 6 1075 1080 2-s2.0-33646779219 10.1053/j.ajkd.2006.02.189 (Pubitemid 43767326)
95. Bergner R., Diel I. J., Henrich D., Hoffmann M., Uppenkamp M., Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006 29 11 534 540 2-s2.0-33750293909 10.1159/000096056 (Pubitemid 44631677)
96. Pfister T., Atzpodien E., Bohrmann B., Bauss F., Acute renal effects of intravenous bisphosphonates in the rat. Basic and Clinical Pharmacology and Toxicology 2005 97 6 374 381 2-s2.0-29744438808 10.1111/j.1742-7843.2005.pto- 160.x (Pubitemid 43028785)
97. Chang J. T., Green L., Beitz J., Tarassoff P., Hei Y.-J., Maladorno D., Renal failure with the use of zoledronic acid. The New England Journal of Medicine 2003 349 17 1676 1679 2-s2.0-0142025453 10.1056/NEJM200310233491721 (Pubitemid 37288581)
98. Markowitz G. S., Fine P. L., Stack J. I., Kunis C. L., Radhakrishnan J., Palecki W., Park J., Nasr S. H., Hoh S., Siegel D. S., D'Agati V. D., Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International 2003 64 1 281 289 2-s2.0-10744228141 10.1046/j.1523-1755.2003. 00071.x (Pubitemid 36714182)
99. Banerjee D., Asif A., Striker L., Preston R. A., Bourgoignie J. J., Roth D., Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. American Journal of Kidney Diseases 2003 41, article E18
100. Cunningham J., Bisphosphonates in the renal patient. Nephrology Dialysis Transplantation 2007 22 6 1505 1507 2-s2.0-34447571974 10.1093/ndt/gfm217 (Pubitemid 47073746)